Bone Health, Bleeding Surprises, and What Rhodiola Actually Does

Episode Script

Thanks Toni. We've got some genuinely interesting research to dig into today — one study that I think actually matters for a lot of women, and two that are worth understanding mostly so you know what stage they're at and don't get oversold on them later.

All three came out this week on PubMed. And because it's Friday, I want to keep this useful and grounded — not a science lecture, just a clear read on what's real and what's still very much in the "maybe someday" category.

Let's start with bone health, because two of today's three studies are about that, and they come from very different directions.

---

The first one is about something called Bushen Huoxue decoction. That's a traditional Chinese herbal formula — "decoction" just means it's brewed, like a tea made from multiple herbs together. The study, published this October, looked at what it does to bone loss in rats whose ovaries had been removed. Removing the ovaries is how researchers simulate menopause in animals, because the drop in estrogen is what drives a lot of the bone breakdown we see in postmenopausal women.

So what did they find? The formula appeared to slow down bone breakdown by targeting a specific cellular pathway. The pathway in question is called NF-κB, which is a signaling system inside cells that, when it gets activated, tells the body to break down more bone. This formula seemed to put the brakes on that process by activating something called sirtuin 1 — basically an internal "calm down" signal that dials back the bone breakdown.

The biology here is legitimate. NF-κB is a real and well-established driver of bone loss. Researchers have been looking at ways to target it for years. So the mechanism they're describing isn't invented — it's a reasonable thing to investigate.

But. And this is a significant but. This was done in rats. Not women. Not even a clinical trial in a small group of women — rats. And I want to be specific about why that matters, because it's not just a technicality.

Rats and humans share a lot of basic biology, which is why animal research is a useful first step. But the history of compounds that looked great in rodent bone studies and then failed — or were never even tested — in humans is very long. The dose used in a rat study doesn't translate directly. The delivery method might not work the same way. And ovariectomized rats, while useful as a model, don't fully replicate the hormonal complexity of a woman going through menopause over years.

So this is a "worth watching" finding, not a "go find this supplement" finding. If you see someone selling a Bushen Huoxue product this week citing this study, that's moving faster than the evidence allows.

---

The second bone study is about a compound called salidroside. That name might not ring a bell, but if you've ever heard of rhodiola — sometimes called rhodiola rosea, sometimes marketed as an adaptogen for stress and energy — salidroside is one of its main active components. It's already in a lot of supplements on the market.

This study, also published October 29th, looked at what salidroside does in the same ovariectomized rat model. The finding: it appeared to protect bone by reducing a specific kind of cellular stress. There's a stress-response system inside cells — the researchers are calling it the PERK-eIF2α-ATF4-CHOP pathway, which is a mouthful — and basically what it means is that when bone-forming cells get overwhelmed and stressed, they start dying off instead of building bone. Salidroside appeared to reduce that stress signal, which kept more of those bone-building cells alive.

Again: real biology, legitimate mechanism, genuinely interesting early finding.

And again: rats.

I want to pause here because salidroside is different from the Bushen Huoxue formula in one important way — it's already widely sold as a supplement, often at doses that were set based on, at best, very limited human data. The rhodiola market is big. The "adaptogen" category is big. And a lot of women in perimenopause and postmenopause are already taking rhodiola products for fatigue, brain fog, mood.

That's not automatically wrong. But the gap between "this compound did something measurable in a rat's bone cells" and "this dose of this rhodiola supplement will protect your bones as a postmenopausal woman" — that gap is enormous. And it's currently unbridged. There are no solid human clinical trials on salidroside for bone loss in postmenopausal women that I can point you to.

So if you're taking rhodiola for energy and you find it helpful, that's a separate question. But if someone starts selling it specifically as a bone-protective supplement for menopause and cites this study — that's getting ahead of the evidence by a considerable distance.

---

The third study today is the one I find most clinically relevant right now, and it's about a completely different topic: a class of drugs called SGLT2 inhibitors.

SGLT2 inhibitors — brand names like Jardiance, Farxiga, and Invokana — are commonly prescribed for type 2 diabetes. In recent years they've also become a go-to for heart failure and chronic kidney disease, because the evidence on those conditions is strong. A lot of postmenopausal women are on one of these drugs, or will be.

This study, published October 29th by Choi and colleagues, looked at a question no one had really studied before: do SGLT2 inhibitors affect the risk of postmenopausal bleeding?

Postmenopausal bleeding — any bleeding that happens more than 12 months after your last period — is always something to take seriously. It can have benign causes, but it can also be a sign of something like uterine cancer, which is why doctors are trained to investigate it promptly.

The researchers used a large real-world dataset comparing women who were newly started on SGLT2 inhibitors to women who were newly started on a different class of diabetes drugs. This kind of study design — called an active-comparator, new-user study — is a reasonably rigorous way to do this kind of comparison, because you're not comparing drug users to non-drug users, which can introduce a lot of bias. You're comparing two similar groups who just got different medications.

What they found: women taking SGLT2 inhibitors had a lower rate of postmenopausal bleeding compared to the comparison group.

That's unexpected. Most of the conversation about these drugs and bleeding has focused on urinary tract effects or genital yeast infections — which are known side effects. Not this.

Now, a few things to hold onto here. This is an observational study — it shows an association, not a proven cause and effect. We don't know the biological reason for the difference yet. It's possible these drugs have some effect on estrogen metabolism or on the uterine lining, but that's speculative right now. It's also possible there's a confounding factor the study didn't fully account for.

But here's my actual take: this is the kind of finding that should prompt more research fast, and it's the kind of finding worth mentioning to your doctor if you're postmenopausal and taking one of these drugs — not because it changes your care, and not because it means you're protected from anything, but because it's a new signal about a drug that millions of women are on.

And the core rule doesn't change. If you have postmenopausal bleeding, you call your doctor. Full stop. No study result, no drug you're on, no supplement you're taking changes that. Postmenopausal bleeding gets evaluated. That's the one thing I'd want every listener to walk away knowing about this study.

What the finding does is open a door — a legitimate research question about a drug class that's becoming increasingly common in this age group. The kind of question your doctor would want to know about, the kind of thing that would show up in a rigorous clinical evidence review. It's early, but it's real, and it's worth watching as more data comes in.

---

Thanks for spending the week with us. If Hot Flasher has been useful to you, hit subscribe wherever you're listening — it's the best way to make sure you don't miss an episode. Have a good weekend, and I'll see you Monday.

---

Sources curated automatically by the Hot Flasher pipeline.